What the ChondroFiller injection costs privately

The cost of a ChondroFiller injection depends on how many boxes of the collagen scaffold your defect requires — not which joint is being treated. Guide costs at London Cartilage Clinic, the first UK clinic to offer ChondroFiller as a standalone injection, are £3,000 for one box, £5,500 for two, and £8,000 for three. Most patients with a single focal defect are treated with one box; larger or multi-compartment lesions progress to two or three, and the treating clinician confirms which tier applies after your assessment.

Every tier is all-inclusive: the consultation, ultrasound guidance, the scaffold product, IV antibiotic cover, and a six-week follow-up appointment are bundled into the one figure — no itemised extras emerge later. That structure makes the procedure straightforward to budget for from the outset.

The clinician's judgement at assessment determines which tier is appropriate, so the confirmed guide cost comes from that conversation rather than from a generic price list. If you hold private medical insurance, partial cover may be available in some cases — that pathway is covered in the section below.

ChondroFiller on the NHS — why it is not currently funded

None of the focal cartilage regeneration options currently available in the UK private sector — ChondroFiller, STACi, or Arthrosamid — are commissioned by the NHS. This is not a gap in provider willingness; it reflects the commissioning process for Class III regenerative devices, which typically lags several years behind CE marking and early clinical adoption. For patients, the practical implication is straightforward: there is no NHS-funded equivalent pathway to benchmark against.

That means every cost comparison in this space is between private options — a like-for-like calculation rather than a private-versus-free one. Patients are not paying a premium over a publicly funded alternative; they are choosing within a self-funded market in which all comparable treatments sit at a similar access level. Understanding that from the outset avoids a common source of confusion when comparing guide costs. The question of whether private medical insurance can offset any of that cost is addressed in the section below.

Private medical insurance and ChondroFiller

For patients with active private medical insurance, the picture is more nuanced than an outright exclusion. Most standard PMI policies do not list ChondroFiller as a default covered benefit, but a recognised billing pathway exists that some insurers have approved on a case-by-case basis.

The procedures are classified using CCSD codes — the billing codes insurers use to categorise treatment for claims purposes. ChondroFiller falls under W3111 (cartilage regeneration with collagen scaffold), and associated appointments may attract W8500 (arthroscopy-related assessment). Approvals have been reported most frequently with Bupa, Aviva, and WPA, though no insurer guarantees cover in advance.

If you hold one of these policies, the practical steps are:

• Contact your insurer before booking, with the relevant CCSD codes to hand.
• Request written pre-authorisation — verbal assurances are not sufficient and will not protect you if a claim is later declined.
• Ask the clinic for an itemised invoice; this allows you to submit an independent reimbursement claim even when full cover is not granted, as partial reimbursement is possible in some cases.

One important caveat: insurer policies and fee schedules change, and the insurance pathways described here were confirmed as of October 2025. Before making any financial decision, verify your current policy terms directly with your insurer and obtain written pre-authorisation for your specific procedure.

Value differences between ChondroFiller, hyaluronic acid, and Arthrosamid

Three products — ChondroFiller, hyaluronic acid, and Arthrosamid — share very little beyond being injected into a joint. Their therapeutic goals differ enough that price-per-injection comparisons become almost meaningless without first matching clinical indication.

ChondroFiller is an acellular collagen scaffold (CE-marked Class III medical device) that gels in situ and supports endogenous repair through acellular matrix-induced chondrogenesis — recruiting the patient's own progenitor cells from surrounding synovium and subchondral bone. It targets isolated focal Grade III/IV cartilage defects where the surrounding tissue remains structurally intact. It is not a lubricant and not a permanent filler.

Hyaluronic acid (viscosupplementation) operates at a different level: it targets joint lubrication and symptom control, not cartilage repair. For patients with mild-to-moderate wear it can reduce friction and improve comfort; for an established focal defect, it does not address the underlying structural problem. Comparing its guide cost against ChondroFiller's is comparing two different therapeutic goals, not two competing solutions to the same one.

Arthrosamid (polyacrylamide hydrogel) occupies a third position. Licensed for diffuse advanced osteoarthritis — including Kellgren-Lawrence Grade IV — it acts as a long-lasting viscoelastic cushion rather than a regenerative scaffold. Its target population is patients with widespread cartilage loss, not isolated focal defects. ChondroFiller and Arthrosamid are clinically complementary rather than interchangeable: the appropriate choice depends on defect pattern, not price.

Private pricing for hyaluronic acid, PRP, and Arthrosamid varies considerably by provider and is not independently verified here. The more instructive value question, in any case, is whether a product is matched to the specific defect — a focal lesion with healthy surrounding borders sits in ChondroFiller's clinical territory; diffuse Grade IV wear sits in Arthrosamid's. Clinical fit is where the meaningful value comparison begins.

Liquid Cartilage™ as the step-up pathway for larger defects

When assessment — imaging, clinical examination, and consultant review — identifies a defect that is too large, too complex, or involves multiple compartments, the stand-alone ChondroFiller injection may not be the most appropriate option. In those cases, Liquid Cartilage™ Surgery (LCS) represents the next step in the treatment hierarchy: an arthroscopic keyhole procedure — a distinct clinical pathway from the outpatient injection service — that combines the ChondroFiller collagen scaffold with the patient's own medicinal signalling cells (MSCs), delivered under arthroscopic vision in a surgical setting.

The guide cost for LCS is published at £9,800 all-in, sitting above the injection tiers (£3,000–£8,000). That gap reflects procedural complexity rather than a difference in the scaffold product alone: theatre admission, anaesthetic, and surgical venue sit behind that figure in a way they do not for an in-clinic, ultrasound-guided appointment.

Neither pathway is inherently superior — they are matched to different defect profiles and different degrees of severity. The decision between the injection and the surgical route is a clinician-led one, made after imaging review and a full consultant assessment.

Getting a ChondroFiller assessment without a referral

For patients outside London, the practical access question is simpler than the clinical one. MSK Doctors clinics in Sleaford (Lincolnshire, NG34) and Grantham (NG31) accept patients directly — no GP referral and no NHS-style waiting list — making the first step straightforward even for those still weighing their options. Appointments can be booked at mskdoctors.com. The initial consultation covers imaging review, clinical examination, and a frank discussion of the realistic range of approaches covered throughout this article; suitability for ChondroFiller, and the treatment tier that fits the defect size and complexity, is determined there rather than assumed in advance. Patients do not need to arrive with a diagnosis or a formed view on which pathway applies to them.